On December 26, 2019, the Board of Directors of Vaxart, Inc. approved a reduction-in-force affecting approximately 50% of employees, which primarily impacted manufacturing personnel. The company expects to incur approximately $375,000 in severance and termination costs and to complete the reduction-in-force by January 31, 2020. The company plan to prioritize and focus resources on partnering opportunities, including norovirus and universal influenza programs, and not on manufacturing capabilities.